Company / Accounts Receivable
LivaNova Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$216.0M
FY2025
5-year range
$183.1M / $216.0M
FY2021-FY2025
Trend
+11.8%
vs FY2024
Sector context
#68 of 138
Health Care
What the data says
At $216M, LivaNova's accounts receivable ranks #68 of 138 in the Health Care sector. Accounts Receivable has fluctuated over the past 10 years, ranging from $183M in FY2022 to $282M in FY2017.
Based on SEC 10-K filings.
$216M in FY2025 with a 5-year CAGR of +3.2%.
Remained stable around $216M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +5.7%
- 5-Year CAGR
- +3.2%
- 10-Year CAGR
- -
Sector benchmark
#68 of 138 in Health CareTop 49% of 138This company $216.0M Sector average $1.3B
▼
-83.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.2%, indicating consistent growth.
- In FY2025, accounts receivable increased 11.8% year-over-year.
- Ranks #68 out of 138 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.84 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $216.0M | +11.8% |
| FY2024 | $193.2M | -10.2% |
| FY2023 | $215.1M | +17.5% |
| FY2022 | $183.1M | -1.2% |
| FY2021 | $185.4M | +0.5% |
| FY2020 | $184.4M | -28.5% |
| FY2019 | $257.8M | +0.6% |
| FY2018 | $256.1M | -9.2% |
| FY2017 | $282.1M | +32.3% |
| FY2016 | $213.3M | +321.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026